The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The Novel Apolipoprotein A5 Is Present in Human Serum, Is Associated with VLDL, HDL, and Chylomicrons, and Circulates at Very Low Concentrations Compared with Other Apolipoproteins
Abstract
Background: The recently discovered apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately fourfold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50–70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor-α agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Despite these compelling molecular biology data, relatively little is known about ApoA5 protein in human serum. Methods: To better understand circulating concentrations and lipoprotein particle distribution of ApoA5, we expressed the recombinant human ApoA5 protein and raised antibodies against both the NH2 and COOH termini. Results: Using the above reagents, we demonstrate for the first time that ApoA5 is present in human serum, although at much lower concentrations than other apolipoproteins such as ApoA1. Using a dual-antibody sandwich ELISA that we developed, we observed ApoA5 concentrations in human serum ranging from 24 to 406 μg/L compared with ∼1 g/L for ApoA1. We also examined the lipoprotein particle distribution of ApoA5 and found that ApoA5 was detectable in VLDL, HDL, and chylomicrons, but not LDL. Conclusions: These data demonstrate for the first time that ApoA5 is a secreted protein present in human serum and is associated with specific lipoprotein particles. In addition, our data indicate that the circulating concentration of human ApoA5 is very low compared with other apolipoproteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921
Prieur, X., Coste, H., & Rodríguez, J. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301302200 · Cited by 194
Willems van Dijk, K., Rensen, P. C., Voshol, P. J., & Havekes, L. M. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200406000-00002 · Cited by 154 · cited 2×
“The fact that the lipoprotein particle distribution of ApoA5 most closely resembles that of ApoC3 is interesting in light of recent data suggesting that ApoC3 and ApoA5 significantly affect triglyceride concentrations, albeit in opposite directions (1, 25).”
Background
Cited by
Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
The effect of heritability and host genetics on the gut microbiota and metabolic syndrome
Lim, M. Y., You, H. J., Yoon, H. S., Kwon, B., Lee, J. Y., Lee, S., Song, Y.-M., Lee, K., Sung, J., & Ko, G. (2017) · Gut · doi:10.1136/gutjnl-2015-311326 · Cited by 345
Merkel, M., Loeffler, B., Kluger, M., Fabig, N., Geppert, G., Pennacchio, L. A., Laatsch, A., & Heeren, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411412200 · Cited by 291
Genetic determinants of plasma triglycerides
Johansen, C. T., Kathiresan, S., & Hegele, R. A. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r009720 · Cited by 263
ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition
Chen, Y. Q., Pottanat, T. G., Zhen, E. Y., Siegel, R. W., Ehsani, M., Qian, Y.-W., & Konrad, R. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100068 · Cited by 82
Self-citationGuan, F., Niu, Y., Zhang, T., Liu, S., Ma, L., Qi, T., Feng, J., Zuo, H., Li, G., Liu, X., et al. (2016) · Scientific Reports · doi:10.1038/srep29586 · Cited by 72
Chan, D. C., Watts, G. F., Nguyen, M. N., & Barrett, P. H. R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000203519.25116.54 · Cited by 70
Qi, L., Liu, S., Rifai, N., Hunter, D., & Hu, F. B. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.006 · Cited by 67
Shu, X., Nelbach, L., Ryan, R. O., & Forte, T. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.004 · Cited by 54
Therapeutic targets of triglyceride metabolism as informed by human genetics
Bauer, R. C., Khetarpal, S. A., Hand, N. J., & Rader, D. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.005 · Cited by 32
Reimund, M., Kovrov, O., Olivecrona, G., & Lookene, A. (2017) · Journal of Lipid Research · doi:10.1194/jlr.d071787 · Cited by 32
Influence of apolipoprotein A-V on hepatocyte lipid droplet formation
Gao, X., Forte, T. M., & Ryan, R. O. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.09.065 · Cited by 16
Ibi, D., Boot, M., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R., Christodoulides, C., Neville, M. J., Koivula, R., Rensen, P. C. N., Karpe, F., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100193 · Cited by 9
Metadata
- Authors
- O’Brien, P. J., Alborn, W. E., Sloan, J. H., Ulmer, M., Boodhoo, A., Knierman, M. D., Schultze, A. E., & Konrad, R. J.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-02-01
- Volume
- 51
- Issue
- 2
- Pages
- 351-359
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2121525857
- Cited by
- 215
- References
- 3
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.